End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
36.46 CNY | -1.09% | +4.29% | +8.35% |
05-15 | Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Directorate and Committee Changes | CI |
04-30 | Tianjin Pharmaceutical's Q1 Profit, Revenue Fall 3% | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The group's high margin levels account for strong profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The firm trades with high earnings multiples: 23.93 times its 2024 earnings per share.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.35% | 3.39B | C | ||
+42.64% | 6.38B | B- | ||
-15.52% | 4.59B | C+ | ||
-11.10% | 3.2B | B- | ||
-4.12% | 2.52B | - | D+ | |
+46.46% | 2B | - | ||
-7.97% | 1.7B | - | - | |
-1.07% | 1.65B | - | - | |
-11.56% | 1.58B | C- | ||
+47.37% | 1.55B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600329 Stock
- Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited